The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Targeting carbon nanotubes against cancer
Open accessAbstract
The use of carbon nanotubes (CNTs) as polyvalent tools for cancer treatment is progressing at a very fast pace. The most promising approach is the targeted delivery of drugs, designed to selectively direct the therapeutic treatment towards the tumours. CNTs may offer several advantages to overcome one of the main limitations of most existing anticancer therapies, namely the lack of selectivity. Herein, an account of the existing literature on CNT-based nanomedicine for cancer treatment is given. The most significant results obtained so far in the field of drug delivery are presented for many anticancer chemotherapeutics (doxorubicin, methotrexate, taxanes, platinum analogues, camptothecine and gemcitabine), but also for immunotherapeutics and nucleic acids. Moreover, the alternative anticancer therapies based on thermal ablation and radiotherapy are discussed. The attention throughout the review is focused on the different targeting strategies proposed so far, mainly based on antibodies, but also on other specifically recognised molecules or on the application of an external magnetic field.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Exploiting the enhanced permeability and retention effect for tumor targeting
Iyer, A. K., Khaled, G., Fang, J., & Maeda, H. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.07.005 · Cited by 1,846
Nagai, H., Okazaki, Y., Chew, S. H., Misawa, N., Yamashita, Y., Akatsuka, S., Ishihara, T., Yamashita, K., Yoshikawa, Y., Yasui, H., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1110013108 · Cited by 535
Self-citation
Cited by
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
Pérez-Herrero, E., & Fernández-Medarde, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.03.018 · Cited by 1,875
Nanomedicine therapeutic approaches to overcome cancer drug resistance
Markman, J. L., Rekechenetskiy, A., Holler, E., & Ljubimova, J. Y. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.019 · Cited by 733
“Current approaches to nanotubes include the incorporation of drugs such as Doxorubicin and Paclitaxel, nucleic acids including antisense oligonucleotides and short interfering RNAs (siRNAs), [12] and the use of nanotubes as contrast agents for imaging.”
Abbasi, R., Shineh, G., Mobaraki, M., Doughty, S., & Tayebi, L. (2023) · Journal of Nanoparticle Research · doi:10.1007/s11051-023-05690-w · Cited by 623
Carbon nanotubes for delivery of small molecule drugs
Wong, B. S., Yoong, S. L., Jagusiak, A., Panczyk, T., Ho, H. K., Ang, W. H., & Pastorin, G. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.08.005 · Cited by 585
Xiao, S., Zhao, T., Wang, J., Wang, C., Du, J., Ying, L., Lin, J., Zhang, C., Hu, W., Wang, L., et al. (2019) · Stem Cell Reviews and Reports · doi:10.1007/s12015-019-09893-4 · Cited by 363
Metadata
- Authors
- Fabbro, C., Ali-Boucetta, H., Ros, T. D., Kostarelos, K., Bianco, A., & Prato, M.
- Venue
- Chemical Communications
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2012
- Volume
- 48
- Issue
- 33
- Pages
- 3911
- ISSN
- 1359-7345 (ISSN-L)
- 1364-548X
- OpenAlex
- W2140093998
- Cited by
- 281
- References
- 3
- FWCI
- 20.75
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting carbon nanotubes against cancer. https://app.cochat.ai/papers/10.1039/c2cc17995d
- The paper
- Fabbro, C., Ali-Boucetta, H., Ros, T. D., Kostarelos, K., Bianco, A., & Prato, M. (2012). Targeting carbon nanotubes against cancer. Chemical Communications. https://doi.org/10.1039/c2cc17995d
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
